PMID- 8097801
OWN - NLM
STAT- MEDLINE
DCOM- 19930602
LR  - 20190611
IS  - 0140-6736 (Print)
IS  - 0140-6736 (Linking)
VI  - 341
IP  - 8853
DP  - 1993 May 1
TI  - Circulating N-terminal atrial natriuretic peptide as a marker for symptomless 
      left-ventricular dysfunction.
PG  - 1105-9
AB  - Early identification of patients with symptomless left-ventricular dysfunction 
      and early pharmacologic intervention may have an impact on the outlook of 
      patients with heart failure. Atrial natriuretic peptide (ANP) is a cardiac 
      hormone that is released as a C-terminal (C-ANP) and an N-terminal peptide 
      (N-ANP). Since N-ANP has reduced clearance rates compared with C-ANP, N-ANP 
      circulates at higher concentrations. Based on the known increased concentration 
      of C-ANP in symptomatic congestive heart failure, our study was designed to 
      evaluate prospectively N-ANP profile and left-ventricular function in subjects 
      with symptomless and symptomatic heart failure, and the role of plasma N-ANP as a 
      marker for early identification of patients with heart failure. 180 patients who 
      were referred for rest and exercise radionuclide angiography for evaluation of 
      left-ventricular function were studied. Blood was taken for measurement of C-ANP 
      and N-ANP before angiography. Patients were grouped according to New York Heart 
      Association (NYHA) heart failure classification and left-ventricular function. 
      Mean (SD) plasma N-ANP concentration in patients with symptomless 
      left-ventricular dysfunction (NYHA class I, n = 70) was 243 (256) pmol/L (range 
      27-922 pmol/L), and was higher (p < 0.001) than in 25 control subjects (28 
      pmol/L). A plasma N-ANP concentration above 54 pmol/L (mean +/- 1.96SD of the 
      control group) had a sensitivity of 90% and a specificity of 92% for detection of 
      patients with symptomless left-ventricular dysfunction. We have shown that plasma 
      N-ANP concentrations are significantly increased in patients with symptomless 
      left-ventricular dysfunction and that this peptide can serve as a marker for 
      diagnosis of such patients.
FAU - Lerman, A
AU  - Lerman A
AD  - Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 
      55905.
FAU - Gibbons, R J
AU  - Gibbons RJ
FAU - Rodeheffer, R J
AU  - Rodeheffer RJ
FAU - Bailey, K R
AU  - Bailey KR
FAU - McKinley, L J
AU  - McKinley LJ
FAU - Heublein, D M
AU  - Heublein DM
FAU - Burnett, J C Jr
AU  - Burnett JC Jr
LA  - eng
GR  - HL0711/HL/NHLBI NIH HHS/United States
GR  - HL36634/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Lancet
JT  - Lancet (London, England)
JID - 2985213R
RN  - 85637-73-6 (Atrial Natriuretic Factor)
SB  - IM
CIN - Lancet. 1993 May 1;341(8853):1124-5. PMID: 8097808
CIN - Lancet. 1993 Jun 19;341(8860):1594-5. PMID: 8099664
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Atrial Natriuretic Factor/*blood
MH  - Female
MH  - Heart Failure/*diagnosis/diagnostic imaging
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Radionuclide Angiography
MH  - Sensitivity and Specificity
MH  - *Ventricular Function, Left
EDAT- 1993/05/01 00:00
MHDA- 2001/03/28 10:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 2001/03/28 10:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
AID - 0140-6736(93)93125-K [pii]
AID - 10.1016/0140-6736(93)93125-k [doi]
PST - ppublish
SO  - Lancet. 1993 May 1;341(8853):1105-9. doi: 10.1016/0140-6736(93)93125-k.